Bipolar Disorder (Manic Depression) Pipeline Assessment, 2023 | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies

 Breaking News
  • No posts were found

Bipolar Disorder (Manic Depression) Pipeline Assessment, 2023 | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies

January 16
18:54 2023
Bipolar Disorder (Manic Depression) Pipeline Assessment, 2023 | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, Treatment Outlook, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 22+ key pharma and biotech companies are working on 22+ pipeline drugs in the Bipolar Disorder (Manic Depression) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Bipolar Disorder (Manic Depression) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Bipolar Disorder Market. 

The Bipolar Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Bipolar Disorder (Manic Depression) Pipeline Analysis

Bipolar Disorder (Manic Depression) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Bipolar Disorder and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Bipolar Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 22+ products under different phases of clinical development like – 

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 

Route of Administration

The Bipolar Disorder Pipeline report provides the therapeutic assessment of emerging drugs by the Route of Administration. Products have been categorized under various ROAs, such as:

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

 

Molecule Type

The Report Covers the Pipeline Products Under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Ongoing Clinical & Commercial Activities will Affect the Bipolar Disorder Therapeutic Segment @

https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight

Bipolar Disorder (Manic Depression) Therapeutics Landscape

There are approx. 22+ key companies which are developing therapies for Bipolar Disorder. Vanda Pharmaceuticals is leading the therapeutics market with its Bipolar Disorder drug candidates in the most advanced stage of clinical development among all the key players.

The Leading Companies in the Bipolar Disorder (Manic Depression) Therapeutics Market Include:

  • Vanda Pharmaceuticals

  • Reviva Pharmaceuticals

  • SK BIOPHARMACEUTICALS

  • Pear Therapeutics

  • Arvelle Therapeutics

  • Janssen Research & Development

  • Sunovion Pharmaceuticals

  • Lyndra Therapeutics

  • ILTOO Pharma

  • COMPASS Pathways

  • NRx Pharmaceuticals

  • Carlsson Research AB

  • Sunovion

  • SAGE Therapeutics

  • Alzamend Neuro

  • OWP Pharmaceuticals

  • Entheogenix Biosciences

And Many Others

 

Bipolar Disorder (Manic Depression) Drugs Covered in the Report Include:

  • Iloperidone: Vanda Pharmaceuticals

  • RP5063: Reviva Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight 

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Bipolar Disorder Current Treatment Patterns

4. Bipolar Disorder – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Bipolar Disorder Late Stage Products (Phase-III)

7. Bipolar Disorder Mid-Stage Products (Phase-II)

8. Bipolar Disorder Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Bipolar Disorder Discontinued Products

13. Bipolar Disorder Product Profiles

14. Key Companies in the Bipolar Disorder Market

15. Key Products in the Bipolar Disorder Therapeutics Segment

16. Dormant and Discontinued Products

17. Bipolar Disorder Unmet Needs

18. Bipolar Disorder Future Perspectives

19. Bipolar Disorder Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-pipeline-insight

Other Trending Healthcare Reports By DelveInsight

Bipolar Disorder (Manic Depression) Market Outlook, 2032

“Bipolar Disorder (Manic Depression) – Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Bipolar Disorder (Manic Depression), historical and forecasted epidemiology as well as the Bipolar Disorder (Manic Depression) market size, share, and trend in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Categories